Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.
Loncaster, Juliette A
Davidson, Susan E
Roberts, Stephen A
Patterson, Adam V
Hunter, Robin D
Stratford, Ian J
West, Catharine M L
AffiliationCancer Research Campaign Experimental Radiation Oncology Group, Paterson Institute for Cancer Research.
MetadataShow full item record
AbstractHypoxic tumors are known to be more malignant, to be more likely to metastasize, and to have a poor prognosis. They are also radio- and chemoresistant. For this reason, it is desirable that a clinically useful marker of hypoxia is found, so that treatment with radiotherapy and bioreductive chemotherapy can be rationally applied to individual patients. Glut-1 is a facilitative glucose transporter that is ubiquitously expressed in normal tissue and expressed at higher levels in a number of tumors. Its potential as an intrinsic hypoxia marker arises from its dual control in hypoxic conditions by reduced oxidative phosphorylation and the hypoxia-inducible factor (HIF-1) oxygen-sensing pathway. Eppendorf histography, by virtue of its proven predictive qualities, is a suitable gold standard used in our laboratory to validate new hypoxia markers. Using this technique, pretreatment pO(2) measurements were performed on 54 patients with locally advanced cervical carcinoma. Then, immunohistochemical staining was used to detect Glut-1 protein in individual tumor biopsy sections. Both measurements were made before initiation of treatment. By using a low-tech scoring system, pO(2) was found to correlate weakly with Glut-1 score (r = 0.28; P = 0.04). To extrapolate this correlation to the known adverse effects of tumor hypoxia on outcome, we examined the prognostic significance of Glut-1 staining in a retrospective series of 121 patients. An absence of Glut-1 significantly increased the likelihood of metastasis-free survival (P = 0.022) but did not significantly effect disease-free or recurrence-free survival. These findings suggest that Glut-1 be an intrinsic marker of hypoxia that can easily be applied in a clinical setting.
CitationGlucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. 2001, 7 (4):928-34 Clin. Cancer Res.
JournalClinical Cancer Research
- Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers.
- Authors: Mayer A, Höckel M, Wree A, Vaupel P
- Issue date: 2005 Apr 1
- GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
- Authors: Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ
- Issue date: 2003 Mar 10
- Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
- Authors: Vordermark D, Brown JM
- Issue date: 2003 Dec
- The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
- Authors: Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ, Kaanders JH
- Issue date: 2006 Jun
- Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
- Authors: Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM, West CM
- Issue date: 2004 Dec 15